A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route

NCT01576523 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Angioedema Types I and II

Interventions

BIOLOGICAL: C1-esterase inhibitor - single intravenous dose
BIOLOGICAL: C1-esterase inhibitor - subcutaneous low dose
BIOLOGICAL: C1-esterase inhibitor - subcutaneous medium dose
BIOLOGICAL: C1-esterase inhibitor - subcutaneous high dose

Sponsor

CSL Behring

Collaborators

[object Object]